[English] 日本語
Yorodumi- EMDB-71719: Structure of alpha2a adrenergic receptor in complex with Go heter... -
+
Open data
-
Basic information
| Entry | ![]() | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Title | Structure of alpha2a adrenergic receptor in complex with Go heterotrimer, scFv16, and N-(5-methylnaphthalen-1-yl)pyridin-4-amine (compound 4905) | |||||||||
Map data | Structure of Alpha2a Adrenergic receptor bound to compound 4905 in complex with Go heterotrimer and scFv16 | |||||||||
Sample |
| |||||||||
Keywords | Receptor / Drug / Complex / GPCR / G-protein / scFv16 / MEMBRANE PROTEIN | |||||||||
| Function / homology | Function and homology informationnegative regulation of uterine smooth muscle contraction / alpha2-adrenergic receptor activity / Adrenaline signalling through Alpha-2 adrenergic receptor / alpha-2C adrenergic receptor binding / epinephrine binding / phospholipase C-activating adrenergic receptor signaling pathway / alpha-1B adrenergic receptor binding / negative regulation of norepinephrine secretion / negative regulation of insulin secretion involved in cellular response to glucose stimulus / negative regulation of epinephrine secretion ...negative regulation of uterine smooth muscle contraction / alpha2-adrenergic receptor activity / Adrenaline signalling through Alpha-2 adrenergic receptor / alpha-2C adrenergic receptor binding / epinephrine binding / phospholipase C-activating adrenergic receptor signaling pathway / alpha-1B adrenergic receptor binding / negative regulation of norepinephrine secretion / negative regulation of insulin secretion involved in cellular response to glucose stimulus / negative regulation of epinephrine secretion / negative regulation of calcium ion-dependent exocytosis / response to alcohol / heterotrimeric G-protein binding / intestinal absorption / positive regulation of potassium ion transport / mu-type opioid receptor binding / thioesterase binding / dopaminergic synapse / corticotropin-releasing hormone receptor 1 binding / thermoception / Surfactant metabolism / negative regulation of neurotransmitter secretion / adenylate cyclase-inhibiting adrenergic receptor signaling pathway / norepinephrine binding / positive regulation of membrane protein ectodomain proteolysis / G protein-coupled dopamine receptor signaling pathway / Adrenoceptors / adrenergic receptor signaling pathway / positive regulation of wound healing / response to morphine / negative regulation of calcium ion transport / positive regulation of epidermal growth factor receptor signaling pathway / parallel fiber to Purkinje cell synapse / Rho protein signal transduction / negative regulation of insulin secretion / negative regulation of lipid catabolic process / regulation of vasoconstriction / postsynaptic modulation of chemical synaptic transmission / cellular response to hormone stimulus / adenylate cyclase-activating adrenergic receptor signaling pathway / presynaptic active zone membrane / muscle contraction / presynaptic modulation of chemical synaptic transmission / adenylate cyclase-inhibiting dopamine receptor signaling pathway / adenylate cyclase-inhibiting serotonin receptor signaling pathway / G protein-coupled serotonin receptor binding / axon terminus / positive regulation of cytokine production / female pregnancy / platelet activation / vasodilation / GABA-ergic synapse / postsynaptic density membrane / epidermal growth factor receptor signaling pathway / G-protein beta/gamma-subunit complex binding / adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway / adenylate cyclase-modulating G protein-coupled receptor signaling pathway / Olfactory Signaling Pathway / Activation of the phototransduction cascade / G protein-coupled acetylcholine receptor signaling pathway / actin cytoskeleton organization / G beta:gamma signalling through PLC beta / Presynaptic function of Kainate receptors / Thromboxane signalling through TP receptor / Activation of G protein gated Potassium channels / Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits / G-protein activation / Glucagon signaling in metabolic regulation / G beta:gamma signalling through CDC42 / Prostacyclin signalling through prostacyclin receptor / Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) / photoreceptor disc membrane / G beta:gamma signalling through BTK / ADP signalling through P2Y purinoceptor 12 / Sensory perception of sweet, bitter, and umami (glutamate) taste / glucose homeostasis / Glucagon-type ligand receptors / Adrenaline,noradrenaline inhibits insulin secretion / Vasopressin regulates renal water homeostasis via Aquaporins / G alpha (z) signalling events / Glucagon-like Peptide-1 (GLP1) regulates insulin secretion / ADP signalling through P2Y purinoceptor 1 / cellular response to catecholamine stimulus / G beta:gamma signalling through PI3Kgamma / ADORA2B mediated anti-inflammatory cytokines production / adenylate cyclase-activating dopamine receptor signaling pathway / cellular response to prostaglandin E stimulus / Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding / GPER1 signaling / heterotrimeric G-protein complex / G alpha (12/13) signalling events / Inactivation, recovery and regulation of the phototransduction cascade / G-protein beta-subunit binding / extracellular vesicle / Thrombin signalling through proteinase activated receptors (PARs) / adenylate cyclase-activating G protein-coupled receptor signaling pathway / signaling receptor complex adaptor activity / GTPase binding / cell body / G protein activity Similarity search - Function | |||||||||
| Biological species | Homo sapiens (human) / ![]() | |||||||||
| Method | single particle reconstruction / cryo EM / Resolution: 2.8 Å | |||||||||
Authors | Srinivasan K / Xu X / Mailhot O / Manglik A / Shoichet B | |||||||||
| Funding support | United States, 1 items
| |||||||||
Citation | Journal: bioRxiv / Year: 2026 Title: Toward a Random Background for Ligand Optimization. Abstract: Ligand optimization is central to drug discovery as hundreds of analogs might be designed and synthesized between an initial hit and a therapeutic candidate. The efficiency of this process is ...Ligand optimization is central to drug discovery as hundreds of analogs might be designed and synthesized between an initial hit and a therapeutic candidate. The efficiency of this process is unclear, at least partly because there is no random background for optimization against which to compare. Such a random background might emerge from synthetically accessible but otherwise systematic random small substitutions across starting ligands, measuring likelihood of achieving a substantial improvement in affinity/potency or other property by any single perturbation. Recent literature and ligand-affinity/potency databases suggest that perhaps 10% of analogs with minor modifications improve upon a parent's potency substantially (by ≥10-fold), but this number is clouded by reporting bias, intentional improvement, and inter-group reproducibility. To begin to establish a background expectation for ligand optimization, we comprehensively and systematically modified 18 lead molecules across six targets with single atom changes; 257 compounds were synthesized. Unexpectedly, 11.2% of these random small perturbation analogs improved potency by ≥10-fold over their parents. Conversely, these more potent analogs typically had worse pharmacokinetics (e.g. reduced metabolic stability, lower plasma free fraction). While it was possible to find analogs where the potency increase compensated for inferior exposure and half-life, resulting in more potent compounds in vivo, overall a frustrated landscape for ligand optimization is revealed. This study begins to establish a background expectation for ligand potency optimization and offers a simple strategy to do so. It also begins to quantify the challenges confronting the field in moving beyond in vitro potency. | |||||||||
| History |
|
-
Structure visualization
| Supplemental images |
|---|
-
Downloads & links
-EMDB archive
| Map data | emd_71719.map.gz | 167.7 MB | EMDB map data format | |
|---|---|---|---|---|
| Header (meta data) | emd-71719-v30.xml emd-71719.xml | 48 KB 48 KB | Display Display | EMDB header |
| FSC (resolution estimation) | emd_71719_fsc.xml | 16.5 KB | Display | FSC data file |
| Images | emd_71719.png | 64.7 KB | ||
| Masks | emd_71719_msk_1.map | 178 MB | Mask map | |
| Filedesc metadata | emd-71719.cif.gz | 10.4 KB | ||
| Others | emd_71719_additional_1.map.gz emd_71719_half_map_1.map.gz emd_71719_half_map_2.map.gz | 88.2 MB 165.2 MB 165.2 MB | ||
| Archive directory | https://data.pdbj.org/pub/emdb/structures/EMD-71719 ftp://data.pdbj.org/pub/emdb/structures/EMD-71719 | HTTPS FTP |
-Related structure data
| Related structure data | ![]() 9ploMC ![]() 14abC ![]() 14amC ![]() 14anC ![]() 14aoC ![]() 14apC ![]() 7iiwC ![]() 7iixC ![]() 7iiyC ![]() 7iizC ![]() 7ij0C ![]() 7ij1C ![]() 7ij2C ![]() 7ij3C ![]() 7ij4C ![]() 7ij5C ![]() 7ij6C ![]() 7ij7C ![]() 7ij8C ![]() 7ij9C ![]() 7ijaC ![]() 7ijbC ![]() 7ijcC ![]() 7ijdC ![]() 7ijeC ![]() 7ijfC ![]() 7ijgC ![]() 7ijhC ![]() 7ijiC ![]() 7ijjC ![]() 7ijkC ![]() 7ijlC ![]() 7ijmC ![]() 9plnC M: atomic model generated by this map C: citing same article ( |
|---|---|
| Similar structure data | Similarity search - Function & homology F&H Search |
-
Links
| EMDB pages | EMDB (EBI/PDBe) / EMDataResource |
|---|---|
| Related items in Molecule of the Month |
-
Map
| File | Download / File: emd_71719.map.gz / Format: CCP4 / Size: 178 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | Structure of Alpha2a Adrenergic receptor bound to compound 4905 in complex with Go heterotrimer and scFv16 | ||||||||||||||||||||||||||||||||||||
| Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||
| Voxel size | X=Y=Z: 0.8189 Å | ||||||||||||||||||||||||||||||||||||
| Density |
| ||||||||||||||||||||||||||||||||||||
| Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||
| Details | EMDB XML:
|
-Supplemental data
-Mask #1
| File | emd_71719_msk_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Additional map: Structure of Alpha2a Adrenergic receptor bound to compound...
| File | emd_71719_additional_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | Structure of Alpha2a Adrenergic receptor bound to compound 4905 in complex with Go heterotrimer and scFv16 | ||||||||||||
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Half map: Structure of Alpha2a Adrenergic receptor bound to compound...
| File | emd_71719_half_map_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | Structure of Alpha2a Adrenergic receptor bound to compound 4905 in complex with Go heterotrimer and scFv16 | ||||||||||||
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Half map: Structure of Alpha2a Adrenergic receptor bound to compound...
| File | emd_71719_half_map_2.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | Structure of Alpha2a Adrenergic receptor bound to compound 4905 in complex with Go heterotrimer and scFv16 | ||||||||||||
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-
Sample components
+Entire : Alpha2a adrenergic receptor in complex with Go heterotrimer, scFv...
+Supramolecule #1: Alpha2a adrenergic receptor in complex with Go heterotrimer, scFv...
+Supramolecule #2: Alpha2a adrenergic receptor with compound 4905
+Supramolecule #3: Signaling complex
+Supramolecule #4: scFv16
+Macromolecule #1: Guanine nucleotide-binding protein G(o) subunit alpha
+Macromolecule #2: Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
+Macromolecule #3: Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
+Macromolecule #4: Alpha-2A adrenergic receptor
+Macromolecule #5: scFv16
+Macromolecule #6: N-(5-methylnaphthalen-1-yl)pyridin-4-amine
-Experimental details
-Structure determination
| Method | cryo EM |
|---|---|
Processing | single particle reconstruction |
| Aggregation state | particle |
-
Sample preparation
| Concentration | 2.6 mg/mL | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buffer | pH: 7.5 Component:
Details: CHS was solubilized in LMNG and GDN prior to diluting into buffers. | |||||||||||||||||||||
| Grid | Model: UltrAuFoil R1.2/1.3 / Material: GOLD / Mesh: 300 / Support film - Material: GOLD / Support film - topology: HOLEY / Pretreatment - Type: GLOW DISCHARGE / Pretreatment - Time: 30 sec. / Pretreatment - Atmosphere: OTHER / Details: 15 mA | |||||||||||||||||||||
| Vitrification | Cryogen name: ETHANE / Chamber humidity: 100 % / Chamber temperature: 277.15 K / Instrument: FEI VITROBOT MARK IV |
-
Electron microscopy
| Microscope | TFS KRIOS |
|---|---|
| Image recording | Film or detector model: GATAN K3 (6k x 4k) / Number grids imaged: 1 / Number real images: 10305 / Average exposure time: 2.0 sec. / Average electron dose: 0.596 e/Å2 |
| Electron beam | Acceleration voltage: 300 kV / Electron source: FIELD EMISSION GUN |
| Electron optics | Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD / Nominal defocus max: 3.0 µm / Nominal defocus min: 1.5 µm / Nominal magnification: 105000 |
| Sample stage | Specimen holder model: FEI TITAN KRIOS AUTOGRID HOLDER / Cooling holder cryogen: NITROGEN |
| Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |
+
Image processing
-Atomic model buiding 1
| Initial model | PDB ID: Chain - Source name: PDB / Chain - Initial model type: experimental model |
|---|---|
| Refinement | Protocol: RIGID BODY FIT / Overall B value: 110.6 |
| Output model | ![]() PDB-9plo: |
Movie
Controller
About Yorodumi



Keywords
Homo sapiens (human)
Authors
United States, 1 items
Citation
























































Z (Sec.)
Y (Row.)
X (Col.)




















































Trichoplusia ni (cabbage looper)
FIELD EMISSION GUN


